Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report.
Jacek JassemNatalia Maria Marek-TrzonkowskaTomasz SmiataczŁukasz ArcimowiczInes PapakEwa JassemJan Maciej ZauchaPublished in: International journal of molecular sciences (2021)
We report a lymphoma patient with profound B-cell deficiency after chemotherapy combined with anti-CD20 antibody successfully treated with remdesivir and convalescent plasma for prolonged SARS-CoV-2 infection. Viral clearance was likely attributed to the robust expansion and activation of TCR Vβ2 CD8+ cytotoxic T cells and CD16 + CD56- NK cells. This is the first presentation of TCR-specific T cell oligoclonal response in COVID-19. Our study suggests that B-cell depleted patients may effectively respond to anti-SARS-CoV-2 treatment when NK and antigen-specific Tc cell response is induced.
Keyphrases
- nk cells
- sars cov
- respiratory syndrome coronavirus
- case report
- end stage renal disease
- coronavirus disease
- regulatory t cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- single cell
- peritoneal dialysis
- intellectual disability
- diffuse large b cell lymphoma
- stem cells
- radiation therapy
- autism spectrum disorder
- mesenchymal stem cells
- squamous cell carcinoma
- patient reported outcomes
- replacement therapy
- combination therapy
- oxidative stress
- locally advanced